INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $981,000 | – | 736,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 9,295,000 | $12,549 | 3.76% |
| Context Capital Management, LLC | 23,076 | $22,612 | 1.81% |
| Weiss Asset Management LP | 16,160,000 | $15,847,974 | 0.94% |
| Anson Funds Management LP | 4,000,000 | $3,920,000 | 0.79% |
| SYQUANT CAPITAL SAS | 2,000,000 | $1,961 | 0.77% |
| DG Capital Management, LLC | 1,101,000 | $1,082,834 | 0.59% |
| Skaana Management L.P. | 2,000,000 | $1,957,600 | 0.48% |
| AQR Arbitrage LLC | 6,130,000 | $6,046,019 | 0.27% |
| OAKTREE CAPITAL MANAGEMENT LP | 7,295,000 | $7,195,058 | 0.10% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $220,658 | 0.04% |